IgA nephropathy trials in Russia

3 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

• Phase 3Taking people
  A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

  Where

  Rostov-on-Don, Saint Petersburg

  Age

  18 years to 100 years

  People

  540 worldwide

  Run by

  Novartis Pharmaceuticals

  See details and how to joinNCT04557462 · EU 2023-508690-92-00
• No phaseTaking people
  Tonsillectomy and Immunosuppression in Caucasian Patients With High-risk IgA-nephropathy

  Where

  Saint Petersburg

  Age

  18 years to 75 years

  People

  240

  Run by

  St. Petersburg State Pavlov Medical University

  See details and how to joinNCT07074951
• No phaseTaking people
  Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial

  Where

  Moscow

  Age

  18 years and over

  People

  30

  Run by

  Botkin Hospital

  See details and how to joinNCT07056595